MX2019012375A - Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). - Google Patents
Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).Info
- Publication number
- MX2019012375A MX2019012375A MX2019012375A MX2019012375A MX2019012375A MX 2019012375 A MX2019012375 A MX 2019012375A MX 2019012375 A MX2019012375 A MX 2019012375A MX 2019012375 A MX2019012375 A MX 2019012375A MX 2019012375 A MX2019012375 A MX 2019012375A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- lfa
- lymphocyte function
- antigen inhibitor
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102100022339 Integrin alpha-L Human genes 0.000 title 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a formulaciones, métodos y kits para el tratamiento de enfermedades del ojo seco. En particular, las composiciones farmacéuticas estabilizadas que comprenden el compuesto de Fórmula I son descritas en la presente para una variedad de usos que incluyen, el tratamiento del síndrome del ojo seco. En un aspecto, se describen métodos e ingredientes para mejorar la estabilidad de composiciones del compuesto de Fórmula I.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739609P | 2012-12-19 | 2012-12-19 | |
| US201361758147P | 2013-01-29 | 2013-01-29 | |
| PCT/US2013/076041 WO2014100135A1 (en) | 2012-12-19 | 2013-12-18 | Lfa-1 inhibitor formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019012375A true MX2019012375A (es) | 2020-01-20 |
| MX391620B MX391620B (es) | 2025-03-19 |
Family
ID=50979140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012375A MX391620B (es) | 2012-12-19 | 2013-12-18 | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). |
| MX2015007540A MX368876B (es) | 2012-12-19 | 2013-12-18 | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007540A MX368876B (es) | 2012-12-19 | 2013-12-18 | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11058677B2 (es) |
| EP (2) | EP3827823A1 (es) |
| JP (1) | JP6373867B2 (es) |
| KR (1) | KR101891144B1 (es) |
| CN (1) | CN104955453B (es) |
| AU (1) | AU2013361579B2 (es) |
| BR (1) | BR112015014367B1 (es) |
| CA (1) | CA2894170C (es) |
| DK (1) | DK2934510T3 (es) |
| EA (2) | EA201791321A1 (es) |
| ES (1) | ES2846724T3 (es) |
| HU (1) | HUE052299T2 (es) |
| IL (1) | IL239490B (es) |
| MX (2) | MX391620B (es) |
| NZ (1) | NZ708821A (es) |
| PL (1) | PL2934510T3 (es) |
| PT (1) | PT2934510T (es) |
| SI (1) | SI2934510T1 (es) |
| WO (1) | WO2014100135A1 (es) |
| ZA (2) | ZA201504404B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106995439B (zh) * | 2016-01-26 | 2019-09-20 | 镇江圣安医药有限公司 | 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途 |
| WO2019171260A1 (en) * | 2018-03-09 | 2019-09-12 | Mankind Pharma Ltd. | Pharmaceutical composition of lifitegrast |
| EP3955926A4 (en) * | 2019-04-18 | 2022-11-30 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| EP3842032A1 (en) | 2019-12-24 | 2021-06-30 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | A pharmaceutical formulation |
| KR20230110516A (ko) * | 2020-10-21 | 2023-07-24 | 아주라 오프탈믹스 엘티디 | 눈 장애의 치료를 위한 화합물 및 방법 |
| CN116211796A (zh) * | 2022-12-30 | 2023-06-06 | 新领先(重庆)医药科技有限公司 | 一种立他司特滴眼液及其制备方法 |
| KR20240109779A (ko) * | 2023-01-05 | 2024-07-12 | 주식회사 종근당 | 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물 |
| KR20250033790A (ko) | 2023-09-01 | 2025-03-10 | 주식회사 와이에스생명과학 | 리피테그라스트 함유 점안 조성물 |
| WO2025093739A1 (en) | 2023-11-02 | 2025-05-08 | Novaliq Gmbh | Semifluorinated alkane compositions comprising lifitegrast |
| WO2025104294A1 (en) * | 2023-11-17 | 2025-05-22 | Bausch + Lomb Ireland Limited | Semifluorinated alkane small molecule lfa-1 antagonist combination compositions for treatment of ocular disorders |
| CN117771174B (zh) * | 2023-12-29 | 2025-07-29 | 鲁南贝特制药有限公司 | 一种立他司特滴眼液及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2694719A (en) | 1949-02-12 | 1954-11-16 | Opplt Jan | Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes |
| DK0642332T3 (da) | 1992-05-13 | 1997-06-16 | Sandoz Ltd | Ophthalmiske præparater indeholdende cyclosporin |
| US5429819A (en) * | 1992-10-14 | 1995-07-04 | Matsushita Electric Industrial Co., Ltd. | Antiviral composition |
| IT1277707B1 (it) * | 1995-12-22 | 1997-11-11 | Chemedica Sa | Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare |
| JP4138910B2 (ja) * | 1997-07-02 | 2008-08-27 | 帝國製薬株式会社 | 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤 |
| RU2149611C1 (ru) * | 1998-04-06 | 2000-05-27 | Московская медицинская академия им. И.М. Сеченова | Капли для лечения воспалительных заболеваний глаз (варианты) |
| DE19954516A1 (de) * | 1999-11-12 | 2001-05-17 | Boehringer Ingelheim Int | Epinastin-haltige Lösungen |
| US6258814B1 (en) * | 2000-10-13 | 2001-07-10 | Schering Corporation | Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep |
| US8877168B1 (en) * | 2002-07-31 | 2014-11-04 | Senju Pharmaceuticals Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| AU2004311577A1 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
| FI119361B (fi) | 2003-09-26 | 2008-10-31 | Raute Oyj | Menetelmä viilun sorvaamiseksi |
| US20060073172A1 (en) * | 2004-10-01 | 2006-04-06 | Schneider L W | Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure |
| PT2444079T (pt) * | 2005-05-17 | 2017-03-03 | Sarcode Bioscience Inc | Composições e métodos para tratamento de distúrbios dos olhos |
| US8101654B2 (en) * | 2005-07-08 | 2012-01-24 | Senju Pharmaceutical Co., Ltd. | Percutaneously absorptive ophthalmic preparation comprising olopatadine |
| US7544893B2 (en) | 2007-07-25 | 2009-06-09 | Thomas & Betts International, Inc. | Extruded wire duct end cap |
| ITRM20080182A1 (it) * | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
| US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| US20090258070A1 (en) | 2008-04-15 | 2009-10-15 | John Burnier | Topical LFA-1 antagonists for use in localized treatment of immune related disorders |
| WO2009128933A1 (en) | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders |
| US20120028929A1 (en) * | 2008-09-19 | 2012-02-02 | Alacrity Bioscience, Inc. | Tetracycline stabilizing formulations |
| EP2346520B1 (en) * | 2008-11-17 | 2014-11-26 | Laila Pharmaceuticals Pvt. Ltd. | Curcuminoids and its metabolites for the application in ocular diseases |
| AU2009347921B8 (en) * | 2009-06-10 | 2014-07-24 | Mitotech Sa | Pharmaceutical composition for use in medical and veterinary ophthalmology |
| KR20110001103A (ko) * | 2009-06-29 | 2011-01-06 | 에스케이케미칼주식회사 | 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물 |
| JP5921439B2 (ja) * | 2009-11-23 | 2016-05-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 結晶形態ｉｉの７−［３，５−ジヒドロキシ−２−（３−ヒドロキシ−５−フェニル−ペント−１−エニル）−シクロペンチル］−ｎ−エチル−ヘプト−５−エナミド（ビマトプロスト）、その調製方法、およびその使用方法 |
| US20120190653A1 (en) * | 2011-01-20 | 2012-07-26 | Dow Pharmaceutical Sciences, Inc. | Therapeutic eye drop comprising doxycycline and a stabilizer |
| EP2675455A4 (en) * | 2011-02-18 | 2014-07-16 | M S Appasamy Associates | OPHTHALMIC COMPOSITION FOR DILATING PUPILS |
| BR112013034055A2 (pt) * | 2011-06-29 | 2017-02-07 | Allergan Inc | alcaftadina para uso no tratamento de urticária |
| EP4420725A3 (en) * | 2012-03-29 | 2025-04-16 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
| CN103230583A (zh) * | 2013-05-17 | 2013-08-07 | 江西省创欣药业集团有限公司 | 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法 |
-
2013
- 2013-12-18 EA EA201791321A patent/EA201791321A1/ru unknown
- 2013-12-18 EP EP20204080.4A patent/EP3827823A1/en not_active Withdrawn
- 2013-12-18 DK DK13865757.2T patent/DK2934510T3/da active
- 2013-12-18 MX MX2019012375A patent/MX391620B/es unknown
- 2013-12-18 US US14/650,955 patent/US11058677B2/en active Active
- 2013-12-18 PL PL13865757T patent/PL2934510T3/pl unknown
- 2013-12-18 WO PCT/US2013/076041 patent/WO2014100135A1/en not_active Ceased
- 2013-12-18 CN CN201380071760.5A patent/CN104955453B/zh active Active
- 2013-12-18 BR BR112015014367-9A patent/BR112015014367B1/pt active IP Right Grant
- 2013-12-18 AU AU2013361579A patent/AU2013361579B2/en active Active
- 2013-12-18 EP EP13865757.2A patent/EP2934510B1/en active Active
- 2013-12-18 JP JP2015549612A patent/JP6373867B2/ja active Active
- 2013-12-18 EA EA201591180A patent/EA028008B1/ru unknown
- 2013-12-18 ES ES13865757T patent/ES2846724T3/es active Active
- 2013-12-18 KR KR1020157019352A patent/KR101891144B1/ko active Active
- 2013-12-18 HU HUE13865757A patent/HUE052299T2/hu unknown
- 2013-12-18 PT PT138657572T patent/PT2934510T/pt unknown
- 2013-12-18 MX MX2015007540A patent/MX368876B/es active IP Right Grant
- 2013-12-18 NZ NZ708821A patent/NZ708821A/en unknown
- 2013-12-18 SI SI201331833T patent/SI2934510T1/sl unknown
- 2013-12-18 CA CA2894170A patent/CA2894170C/en active Active
-
2015
- 2015-06-18 IL IL239490A patent/IL239490B/en active IP Right Grant
- 2015-06-18 ZA ZA2015/04404A patent/ZA201504404B/en unknown
-
2016
- 2016-11-22 ZA ZA2016/08069A patent/ZA201608069B/en unknown
-
2021
- 2021-06-09 US US17/342,631 patent/US20220000859A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012375A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1120529T1 (el) | Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων | |
| CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
| CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
| CY1121736T1 (el) | Άλατα aramchol | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| ECSP13013050A (es) | Formulación para anticuerpo anti- 4 7 | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| EA202191513A1 (ru) | Снижение вязкости фармацевтических составов |